JLE

Journal de Pharmacie Clinique

MENU

Supply chain of chimeric receptor T cells (CAR-T cells): what are the roles of the hospital pharmacist? Volume 41, issue 1, Mars 2022

Authors
1 CHU Lille, Institut de pharmacie, rue Philippe Marache, 59000 Lille, France
2 Université de Lille, ULR 7365, Groupe de recherche sur les formes injectables et les technologies associées (GRITA), 59000 Lille, France
3 Université de Lille, Inserm, Infinite, U1286, 59000 Lille, France
4 CHU Lille, Service des maladies du sang, hôpital Huriez, 59000 Lille, France
* Correspondance

Chimeric receptor T-cells (CAR-T cells) are a new class of drugs that require hospitals to adapt in order to manage these new treatments and ensure the patients’ safety. In addition to the imperatives of medical care pathways, another essential point is the structuring of the intra-hospital supply chain for these drugs. The objective of this article is to describe the role of the hospital pharmacist in the implementation of the supply chain within the institution but also in his role as clinical pharmacist. The different steps of the supply chain are detailed by recalling the role of the pharmacist described in the regulation, and his/her place within the multi-professional team involved in this process, from the feasibility study to the follow-up of patients during hospitalization. After 3 years of activity in our university hospital, perspectives for improvement are also presented to further secure this pharmaceutical circuit and optimize patient care.